AOD 9604 has a limited but generally reassuring safety profile from clinical trials, with no major adverse events reported in studies lasting up to 24 weeks. However, it was never approved by the FDA, its pharmaceutical development was abandoned in 2007, and the FDA has flagged potential safety concerns with compounded versions now sold through clinics and online retailers. The short answer: the peptide itself appeared well-tolerated in controlled studies, but what you can actually buy today is a different question entirely.
What AOD 9604 Is
AOD 9604 is a synthetic fragment of human growth hormone, specifically a modified copy of amino acids 177 through 191. This small section of the growth hormone molecule is responsible for its fat-burning activity. Researchers isolated it in the hope of getting growth hormone’s fat loss benefits without the problematic side effects that come with full growth hormone therapy, like insulin resistance and abnormal tissue growth.
The peptide works by stimulating fat breakdown in adipose tissue and increasing fat oxidation (the rate at which your body burns fat for energy). Importantly, it does this through a different pathway than full growth hormone. It does not raise levels of IGF-1, the growth factor linked to many of growth hormone’s unwanted effects.
What Clinical Trials Actually Showed
AOD 9604 went through several phases of human testing. In a 12-week randomized trial, subjects taking 1 mg per day orally lost an average of 2.6 kg compared to 0.8 kg in the placebo group. That modest result led to a larger 24-week trial involving 536 obese subjects. The larger trial failed to show significant weight loss, and development was terminated in 2007.
The safety data from these trials was the more interesting part. Oral glucose tolerance testing showed that AOD 9604 had no negative effect on carbohydrate metabolism. This is a meaningful distinction from full growth hormone, which can cause glucose intolerance and insulin resistance with prolonged use. In one clinical study, obese women given growth hormone developed decreased glucose tolerance over six months. AOD 9604 did not produce this effect.
In fact, the data hinted at a possible benefit. Among trial participants who already had impaired glucose tolerance (a pre-diabetic state), those receiving AOD 9604 were less likely to progress to diabetes during the study than those taking placebo. Animal studies using a precise insulin-measurement technique confirmed that chronic AOD 9604 treatment had no adverse effect on insulin sensitivity, while full growth hormone did.
What the FDA Says
AOD 9604 is not FDA-approved for any medical use. It was never granted a “Generally Recognized as Safe” (GRAS) designation, despite claims you may encounter online. The FDA’s official GRAS Notice Inventory contains no listing for AOD 9604.
More significantly, the FDA has specifically flagged compounded AOD 9604 products as potentially risky. The agency’s concerns center on three issues: the peptide may trigger immune reactions depending on how it’s administered, peptide-related impurities in compounded products are difficult to control, and the overall safety data is too limited for the FDA to confirm the substance is safe for human use. The FDA has also noted serious adverse events that may be associated with AOD 9604, though it stopped short of confirming a causal link.
AOD 9604 appeared on the FDA’s list of bulk drug substances nominated for compounding use but was subsequently withdrawn from that list. This means compounding pharmacies that previously prepared it under certain regulatory frameworks may no longer have that option.
The Difference Between Trial Safety and Real-World Safety
The clinical trials used pharmaceutical-grade AOD 9604 manufactured under strict quality controls and administered at a known dose (1 mg per day, orally). What’s available today through peptide clinics, online vendors, and compounding pharmacies is a fundamentally different product in terms of quality assurance.
Peptides are fragile molecules. They degrade if stored improperly, and small manufacturing errors can introduce impurities that cause immune reactions or other problems. The FDA’s concern about “peptide-related impurities and API characterization” is essentially a warning that compounded versions may not contain what they claim, or may contain harmful byproducts. A peptide that was safe in a controlled clinical setting can become unsafe when produced without pharmaceutical-grade oversight.
The route of administration also matters. Clinical trials primarily studied oral dosing. Many current products are sold as subcutaneous injections, which bypass the digestive system and interact with the immune system differently. The FDA specifically noted that immunogenicity (the risk of your immune system reacting to the peptide as a foreign substance) may vary by route of administration.
What the Safety Data Doesn’t Cover
The longest published human trial lasted 24 weeks. There is no data on what happens with use beyond six months. There is no published data on interactions with common medications, effects during pregnancy, or safety in people with liver or kidney disease. No studies have examined AOD 9604 in combination with other peptides, even though “peptide stacking” is common among people who use these products.
The lack of detailed adverse event reporting from the clinical trials is also a gap. While the trials did not flag major safety concerns, specific side effect rates (how many people experienced headaches, injection site reactions, digestive issues, or other problems) are not available in the published literature. The trials reported that the peptide was “well-tolerated,” but that characterization lacks the granularity you’d normally see in a drug safety profile.
Metabolic Safety Compared to Growth Hormone
The clearest safety advantage of AOD 9604 is what it doesn’t do. Full growth hormone therapy carries well-documented risks: it raises IGF-1, can cause joint pain and fluid retention, worsens blood sugar control, and with long-term use may increase cancer risk. AOD 9604 was specifically designed to avoid these problems by using only the fat-metabolism fragment of the hormone.
Animal studies confirmed this selectivity. In obese mice, chronic growth hormone treatment depressed glucose oxidation and raised blood sugar levels. AOD 9604 caused neither of these effects. The peptide also did not raise IGF-1 levels, which means it lacks the growth-promoting activity that makes full growth hormone potentially dangerous with extended use. In obese rats, 19 days of daily oral AOD 9604 reduced weight gain by over 50% without affecting insulin sensitivity.
This metabolic safety profile is the primary reason the peptide continues to attract interest despite its commercial failure as a weight loss drug. It appeared to be a genuinely safer alternative to growth hormone for fat metabolism, even if the fat loss effect was too small to justify FDA approval.
The Bottom Line on Risk
In controlled clinical trials with pharmaceutical-grade product, AOD 9604 showed a favorable short-term safety profile with no significant adverse metabolic effects. The peptide did not disrupt blood sugar, insulin sensitivity, or IGF-1 levels in the way full growth hormone does. But the substance was never approved, development was abandoned 18 years ago, long-term data doesn’t exist, and the FDA has raised specific concerns about the compounded products currently on the market. If you’re considering AOD 9604, the safety question isn’t just about the molecule itself. It’s about the source, purity, and route of administration of whatever product you’d actually be using.